148 related articles for article (PubMed ID: 21087604)
21. Intra- and extracellular signaling by endothelial neuregulin-1.
Iivanainen E; Paatero I; Heikkinen SM; Junttila TT; Cao R; Klint P; Jaakkola PM; Cao Y; Elenius K
Exp Cell Res; 2007 Aug; 313(13):2896-909. PubMed ID: 17499242
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
23. Autocrine, paracrine and juxtacrine signaling by EGFR ligands.
Singh AB; Harris RC
Cell Signal; 2005 Oct; 17(10):1183-93. PubMed ID: 15982853
[TBL] [Abstract][Full Text] [Related]
24. Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA.
Li J; Ma C; Huang Y; Luo J; Huang C
Oncogene; 2003 Jan; 22(2):211-9. PubMed ID: 12527890
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor in cultured human retinal pigment epithelial cells.
Yan F; Hui YN; Li YJ; Guo CM; Meng H
Ophthalmologica; 2007; 221(4):244-50. PubMed ID: 17579290
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
27. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors.
Segatto O; Anastasi S; Alemà S
J Cell Sci; 2011 Jun; 124(Pt 11):1785-93. PubMed ID: 21576352
[TBL] [Abstract][Full Text] [Related]
28. [Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4].
Ye F; Guo DS; Niu HQ; Tao SZ; Ou YB; Lu YP; Lei T
Ai Zheng; 2004 Oct; 23(10):1149-54. PubMed ID: 15473925
[TBL] [Abstract][Full Text] [Related]
29. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
30. LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.
Kou C; Zhou T; Han X; Zhuang H; Qian H
Biochem Biophys Res Commun; 2015 Aug; 464(2):519-25. PubMed ID: 26159916
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
[TBL] [Abstract][Full Text] [Related]
32. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.
Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX
Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540
[TBL] [Abstract][Full Text] [Related]
33. LRIG1 extracellular domain: structure and function analysis.
Xu Y; Soo P; Walker F; Zhang HH; Redpath N; Tan CW; Nicola NA; Adams TE; Garrett TP; Zhang JG; Burgess AW
J Mol Biol; 2015 May; 427(10):1934-48. PubMed ID: 25765764
[TBL] [Abstract][Full Text] [Related]
34. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
Guo D; Han L; Shu K; Chen J; Lei T
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120
[TBL] [Abstract][Full Text] [Related]
36. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.
Thomasson M; Wang B; Hammarsten P; Dahlman A; Persson JL; Josefsson A; Stattin P; Granfors T; Egevad L; Henriksson R; Bergh A; Hedman H
Int J Cancer; 2011 Jun; 128(12):2843-52. PubMed ID: 21128282
[TBL] [Abstract][Full Text] [Related]
37. A protein interaction network centered on leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) regulates growth factor receptors.
Faraz M; Herdenberg C; Holmlund C; Henriksson R; Hedman H
J Biol Chem; 2018 Mar; 293(9):3421-3435. PubMed ID: 29317492
[TBL] [Abstract][Full Text] [Related]
38. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
39. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
[TBL] [Abstract][Full Text] [Related]
40. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity.
Wu X; Hedman H; Bergqvist M; Bergström S; Henriksson R; Gullbo J; Lennartsson J; Hesselius P; Ekman S
Acta Oncol; 2012 Jan; 51(1):69-76. PubMed ID: 21417672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
